) LVMI decreased with treatment, treatment failed to increase EF in either group (1.2Ϯ10.8% and 2.7Ϯ10.7%, respectively). In contrast, in patients with inappropriate LV hypertrophy (LVM inappr Ͼ150%; nϭ33) LVM inappr decreased (Ϫ32Ϯ27%; PϽ0.0001) and EF increased (5.0Ϯ10.3%; PϽ0.05) after treatment, whereas in patients with an LVM inappr Յ150% (nϭ135), neither LVM inappr (Ϫ0.5Ϯ23%) nor EF (0.9Ϯ10.3%) changed with therapy. With adjustments for circumferential LV wall stress and other confounders, whereas on-treatment decreases in LVM or LVMI were weakly related to an attenuated EF (partial rϭ0.17; PϽ0.05), on-treatment decreases in LVM inappr were strongly related to increases in EF even after further adjustments for LVM or LVMI (partial rϭϪ0.63 [CI, Ϫ0.71 to Ϫ0.52]; PϽ0.0001). In conclusion, decreases in LVM inappr are strongly related to on-treatment increases in EF beyond changes in LVM and LVMI. LV hypertrophy can, therefore, be viewed as a compensatory change that preserves EF, but when in excess of that predicted by stroke work, it can be viewed as a pathophysiological process accounting for a reduced EF. 1-7 and the development of a reduced ejection fraction (EF) 8 independent of myocardial infarction. LV mass (LVM) may, therefore, determine the progression to heart failure with a reduced rather than a preserved EF. 9, 10 However, in keeping with the classic tenet that LVH is a compensatory response to LV load, an increased LVM 11-13 or on-treatment decreases in LVM 14 have been associated with an unchanged EF. Moreover, LVH may even be associated with an enhanced EF for that predicted by wall stress, 15 and on-treatment decreases in LVM have been related to reductions rather than increases in indices of systolic LV chamber function. 16 There is, therefore, considerable uncertainty as to whether LVH contributes to decreases in systolic chamber function.
L eft ventricular (LV) hypertrophy (LVH) is a predictor of heart failure [1] [2] [3] [4] [5] [6] [7] and the development of a reduced ejection fraction (EF) 8 independent of myocardial infarction. LV mass (LVM) may, therefore, determine the progression to heart failure with a reduced rather than a preserved EF. 9, 10 However, in keeping with the classic tenet that LVH is a compensatory response to LV load, an increased LVM [11] [12] [13] or on-treatment decreases in LVM 14 have been associated with an unchanged EF. Moreover, LVH may even be associated with an enhanced EF for that predicted by wall stress, 15 and on-treatment decreases in LVM have been related to reductions rather than increases in indices of systolic LV chamber function. 16 There is, therefore, considerable uncertainty as to whether LVH contributes to decreases in systolic chamber function.
One possibility that may explain discrepancies in the ability to show consistent relations between LVM or LVM index (LVMI) and a reduced systolic LV chamber function [11] [12] [13] [14] [15] [16] is that absolute LVM and LVMI may incorporate a component of LVH considered compensatory in nature, whereas there may also be a component of LVH that contributes to decompensation. In this regard, LVM in excess of that predicted by workload (ie, stroke workϭblood pressure [BP]ϫstroke volume), termed "inappropriate LVM" (LVM inappr ), 17 is inversely associated with systolic LV chamber function. [18] [19] [20] [21] [22] [23] [24] [25] However, these relationships have largely been demonstrated in cross-sectional studies [18] [19] [20] [21] [22] [23] [24] and are at odds with on-treatment decreases in systolic LV chamber function associated with LVH regression. 16 Inverse LVM inappr ϪLV systolic chamber function relations [18] [19] [20] [21] [22] [23] [24] may, therefore, reflect compensatory increases in LVM as a consequence of systolic dysfunction or associated confounding effects. Although one previous study has reported that on-treatment regression but not persistence of LVM inappr is associated with an improved EF, 25 whether increases in EF in the participants showing regression of LVM inappr in that study were independent of or stronger than changes in LVM or LVMI is uncertain. To further explore the possibility that increases in LVM beyond workload and absolute LVM may contribute toward a decreased systolic LV chamber function, in the present study we, therefore, aimed to evaluate whether treatment-induced decreases in LVM inappr in mild-to-moderate hypertension are associated with increases in EF independent of and more strongly than LVM or LVMI.
Methods

Study Group
The present study was conducted according to the principles outlined in the Helsinki Declaration. The University of the Witwatersrand Committee for Research on Human Subjects approved the protocol (approval No. M940106). Participants gave informed, written consent. The study design has been described previously. 26, 27 Hypertensives of black African descent 18 to 70 years of age, free of clinically significant cardiovascular and noncardiovascular disease, were enrolled. Hypertension was diagnosed after a 2-week placebo run-in period, if daytime ambulatory diastolic BP was 90 to 114 mm Hg.
Eligible patients were randomly assigned to receive nifedipine gastrointestinal system at 30.0 mg/d, verapamil slow release at 240.0 mg/d, hydrochlorothiazide at 12.5 mg/d, or enalapril at 10.0 mg/d, and patients were followed up at monthly intervals for 4 months. 26 At each monthly visit, uptitration of therapy or the addition of therapy occurred as described. 26 If target BP was not achieved (daytime diastolic BP Ͻ90 mm Hg), at 1 month, the daily dose of therapy was increased (nifedipine gastrointestinal system, 60 mg; verapamil slow release, 360 mg; hydrochlorothiazide, 25 mg; and enalapril, 20 mg), and at 2 months in patients receiving nifedipine gastrointestinal system (enalapril, 10 mg/d; carvedilol, 25 mg/d) or verapamil slow release were added or the dose of nifedipine gastrointestinal system was increased to 90 mg/d. In patients receiving verapamil slow release at 2 months, the dose could be increased to 480 mg/d. In those receiving hydrochlorothiazide 25.000 mg/d, reserpine 0.125 mg/d could be added, and in those receiving enalapril 20.0 mg/d, hydrochlorothiazide 12.5 mg/d could be added.
Of the 409 patients randomized, 233 were eligible for inclusion in the substudy because echocardiograms were of sufficient quality. Of the latter patients, 23 were withdrawn before 4 months, and 42 did not have all measurements. Thus, data in 168 participants were available for analysis. High-quality echocardiograms could not be obtained in 176 participants because of the high participant rate of obese females with a generalized fat distribution, including the thoracic region.
Blood Pressure
High-quality conventional BP measurements were obtained by trained nurse technicians according to guidelines 28, 29 using a standard mercury sphygmomanometer, as described previously. 26, 27 Ambulatory 24-hour, day, and night BP were determined using SpaceLabs monitors (model 90207), as described previously.
26,27
Echocardiography M-mode, 2D pulse and color Doppler echocardiography was performed as described previously, 26, 27 and M-mode variables were analyzed according to the American Society of Echocardiography convention. 30 All of the participants were assessed for mitral valve abnormalities as determined using 2D and color Doppler imaging. All of the measurements were recorded and analyzed offline by experienced investigators who were unaware of the clinical data of the participants. LV mass (LVM) was determined using a standard formula 31 and indexed (LVMI) to height 2.7 . LV mean wall thickness was calculated as the mean of septalϩposterior wall thickness and LV relative wall thickness as (septalϩposterior wall thickness)/LV end diastolic diameter. An LVMI Ͼ51 g/m 2.7 was considered to be increased. 32 LV EF (biplane Simpson) and midwall fractional shortening (FSmid) were calculated to determine LV chamber and myocardial systolic function, respectively, using standard formulas (see the online-only Data Supplement for FSmid calculation). The calculation of FSmid using a modified ellipsoidal model as described previously 33 accounts for epicardial migration of the midwall during systole. Stroke volume was evaluated from the difference between LV end diastolic and systolic volumes determined using both the Teichholz 34 and the z-derived 35 methods. Circumferential LV systolic wall stress was calculated as described previously (see the online-only Data Supplement for calculation). 13 The extent of LVM inappr was determined from predicted LVM as described by others, 36 where predicted LVM was calculated as 55.37ϩ(6.64ϫheight 2.7 )ϩ(0.64ϫ[systolic BPϫstroke volumeϫ 0.014])Ϫ(18.07ϫsex), where male sex is 1 and female sex is 2 and where stroke volume was calculated from LV volumes assessed from the z-derived method. 35 Inappropriate LVM was expressed either as actualϪpredicted LVM in grams or percentage of actual LVM/ predicted LVM. An LVMI inappr Ͼ150% was considered to be increased. This threshold was identified from the upper 95% CI for LVMI inappr determined in 140 of 678 participants from a community-based study without clinically significant disease and normal blood parameters who were normotensive, nondiabetic, and had a body mass index Ͻ30 kg/m 2 . In these participants the upper 95% CI for LVMI was 51.8 g/m 2.7 .
Data Analysis
Database management and statistical analyses were performed with SAS software, version 9.1 (SAS Institute Inc., Cary, NC). Continuous data are reported as meanϮSD. Unadjusted means and proportions were compared by the large-sample z test and the 2 statistic, respectively. Changes in variables over the 4-month treatment period and a comparison of these changes between groups with versus without increases in LVM inappr or LVMI were determined using a 2-way ANOVA with a Tukey post hoc test. A comparison of changes in adjusted EF between groups with and without increases in LVM inappr or LVMI was determined using multivariate regression analysis. Independent relations between baseline or change in LVM, LVMI, or LVM inappr and baseline or change in EF were assessed from multivariate linear regression analysis with appropriate adjustors. Adjustments included age, sex, circumferential LV systolic wall stress, diabetes mellitus, pulse rate, previous treatment for hypertension, regular smoking, regular alcohol intake, and body weight, because in bivariate or multivariate models these parameters were associated with EF, LVM, LVMI, or LVM inappr . The use of carvedilol was also included as an adjustor, because a modestly higher proportion of participants with an increased LVM inappr were receiving this agent. Z statistics were used to compare correlation coefficients.
Results
Participant Characteristics
A high proportion of participants were obese (Table 1) . A total of 19.6% had inappropriate increases in LVM, and 66.7% had LVH (LVMI Ͼ51 g/m 2.7 ). As compared with the 176 nonparticipants, the 168 participants who had all of the data available for analysis were younger and less obese (Table 1) . Otherwise, participants with data available had similar characteristics as compared with nonparticipants, including similar conventional and ambulatory BP values ( Table 1) .
Suitability of the LVM inappr Calculation
In contrast to strong positive correlations between LVM (or LVMI) and stroke work (rϭ0.56 -0.60; PϽ0.0001), LVM inappr was unrelated to stroke work (rϭ0.001; Pϭ0.99).
Clinical and Demographic Factors at Baseline Independently Associated With LVM inappr
On bivariate analysis age, female sex, regular alcohol intake, body mass index, and body weight were positively associated with LVM inappr at baseline (PϽ0.05 to Ͻ0.0001). In a multivariate model, sex (PϽ0.05), body mass index (PϽ0.0001), and body weight (PϽ0.0001; separate model from body mass index) were independently and positively related to LVM inappr .
Relationships Between LV Systolic Function and LVM inappr , LVM, or LVMI at Baseline
Strong relationships between baseline LVM inappr and both baseline EF and FSmid independent of confounders and either LVM or LVMI were noted (Table S1 , available in the online-only Data Supplement). In contrast, neither baseline LVM nor LVMI was independently related to either baseline EF or FSmid (Table S1 ).
Treatment Effects in the Whole Group
Four months of antihypertensive therapy in all of the participants resulted in decreases in conventional and ambulatory BP, LV wall stress, stroke work, LVM, LVMI, and LVM inappr (Table 2 ) and a modest increase in EF but no changes in FSmid or LV relative wall thickness (Table 2) .
Treatment Effects on BP, Wall Stress, and Stroke Work in Patients With or Without an Increased LVM inappr or LVMI
At the end of the 4-month treatment period, participants with an increased LVM inappr or LVMI were receiving similar drug classes as compared with participants with an appropriate LVM or normal LVMI except for a modestly greater use of carvedilol in the group with an increased LVM inappr (Table  S2) . Antihypertensive treatment of participants with an increased LVM inappr resulted in decreases in conventional or 24-hour BP and circumferential LV systolic wall stress and stroke work, which were not statistically different from those noted in participants with an appropriate LVM (Table 3) . However, as compared with participants with a normal LVMI, antihypertensive treatment of participants with an increased LVMI resulted in greater decreases in systolic BP and stroke work (Table 3) .
Treatment Effects on LV Structure in Patients With or Without an Increased LVM inappr or LVMI
Treatment of participants with an increased LVM inappr or LVMI resulted in decreases in all of the LV structural parameters (Table 4) . In participants with an appropriate LVM, treatment also decreased LVM but not other LV structural parameters (Table 4 ). The decrease in LV structural parameters with treatment was greater in participants with an increased LVM inappr as compared with those with an appropriate LVM (Table 4 ). In participants with a normal LVMI, treatment did not alter LV structure, and treatment-induced decreases in LVM, LVMI, LV mean wall thickness, and LV end diastolic diameter were greater in participants with an increased LVMI than in those without (Table 4) .
Treatment Effects on LV Systolic Function in Patients With or Without an Increased LVM inappr or LVMI
As compared with patients with an appropriate LVM, where unadjusted and multivariate-adjusted EF failed to improve with antihypertensive therapy, in patients with an increased LVM inappr , unadjusted and multivariate-adjusted EF increased with antihypertensive therapy (Table 5 ). In contrast, no significant unadjusted or multivariate-adjusted changes in EF were noted in patients with either an increased or a normal LVMI (Table 5) . No significant treatment effects on FSmid were noted (Table 5) . 
Relationship Between On-Treatment Change in LVM, LVMI, or LVM inappr and LV EF
With or without adjustments for potential confounders, ontreatment decreases and percentage decreases in LVMI inappr were strongly associated with an increase and percentage increase in EF (Table 6 ). The strength of the multivariateadjusted relationships was unchanged with further adjustments for baseline EF included in the model (Table 6 ). In contrast, decreases and percentage decreases in LVM and LVMI were modestly associated with a decrease and percentage decrease in EF (Table 6 ). The positive relationships between LVM or LVMI and EF were abolished with further adjustments for baseline EF (Table 6 ). The inverse relationships between change in or percentage change in LVM inappr and change in or percentage change in EF were far stronger than the relationships between change in or percentage 
Discussion
The main finding of the present study is that, in the treatment of mild-to-moderate hypertension over a 4-month period, in contrast to a modest treatment-induced attenuation in EF accompanying decreases in LVM and LVMI, on-treatment decreases in LVM inappr were strongly and independently related to improvements in EF. Importantly, relationships between on-treatment changes in LVM inappr and EF were unaltered by adjustments for LVM or LVMI and were noted to be far stronger than relationships between on-treatment changes in LVM or LVMI and EF.
Although one previous study has demonstrated that ontreatment regression but not persistence of LVM inappr is associated with an improved EF, 25 whether changes in EF associated with decreases in LVM inappr are independent of or stronger than changes in LVM or LVMI is uncertain. To the best of our knowledge, the present study provides the first prospective, intervention data to show that regression of LVH as indexed by LVM inappr is associated with improvements in EF beyond that of LVM or LVMI. The present study therefore supports the notion that LVH in excess of that predicted by stroke work, rather than absolute LVM, accounts for a decrease in LV systolic chamber function.
Previous studies showing inverse relationships between LVM inappr and indices of systolic chamber function [18] [19] [20] [21] [22] [23] [24] [25] have largely been reported in cross-sectional studies conducted in select clinical samples, [18] [19] [20] [21] [22] [23] [24] and none have demonstrated these effects beyond LVM or LVMI. Such relationships may, therefore, reflect a compensatory increase in LVM in response to a depressed LV systolic function, [18] [19] [20] [21] [22] [23] [24] to residual confounding effects, [18] [19] [20] [21] [22] [23] [24] [25] or to an effect that depends on absolute LVM. [18] [19] [20] [21] [22] [23] [24] [25] With respect to whether the relationships shown in the present study may also be attributed to a decrease in LVM in response to a reduction in LV systolic chamber function, there is little preclinical or clinical evidence to our knowledge to indicate that antihypertensive therapy is able to increase LV systolic chamber function independent of load over a short duration of therapy (4 months). In contrast, there is substantial evidence to show that antihypertensive therapy in part regresses LVH over this time period. It is, therefore, likely that, in the present study, antihypertensive therapy regressed LVM inappr , and the reduced LVM inappr or associated myocardial changes consequently enhanced EF.
Previous studies have demonstrated that regression of LVH after treatment with antihypertensive therapy is associated with either no change 14 or with decreased 16 rather than improved indices of systolic LV chamber function. Similarly, in the present study we show that decreases in LVM or LVMI are associated with a modest attenuation rather than an increase in EF with antihypertensive therapy. Together with the often enhanced EF observed relative to that predicted from LV wall stress in LVH, 15 such data have previously cast doubt on inverse relationships between LVH and EF being attributed to LVH, accounting for a decreased LV systolic chamber function. However, as in the present study, ontreatment decreases in LVM inappr were strongly and independently associated with the opposite effect on EF (an increase); the present study provides evidence to support the notion that LVH or factors related to LVH may be responsible for decreases in systolic LV chamber function but that LVM inappr and not absolute LVM or LVMI accounts for this effect.
Although not a primary outcome of the present study, it is important to consider the potential mechanisms for the on-treatment LVM inappr -EF relations observed. In this regard, EF is in part determined by myocardial systolic function, which is indexed by FSmid. Despite our ability to show strong inverse relations between FSmid and LVM inappr independent of LVM or LVMI at baseline, after 4 months of antihypertensive therapy, no significant relationships between change in FSmid and change in LVM inappr were noted. These data suggest that on-treatment changes in FSmid over a short treatment period are too small to show relations with decreases in LVM inappr unless larger study samples are used. Indeed, previous studies have demonstrated that LVH regression after 3 months of antihypertensive treatment was associated with only a 0.6% increase in FSmid and required 152 patients to show a trend for significance. 14 The exact mechanisms at a myocardial level that may account for the improved LV systolic function associated with regression of an increased LVM inappr are also unclear. This may reflect the regeneration of cardiomyocytes damaged by LVH-associated apoptosis and necrosis. However, the short duration over which LV systolic chamber function increased suggests an alternative mechanism, such as an improved cardiomyocyte function. In this regard, LVM inappr may be accompanied by an imbalance in myocardial oxygen supply:demand ratios, a change that promotes cardiomyocyte dysfunction. With a decrease in LVM inappr , the balance between myocardial oxygen supply and demand may be restored and function improved.
Caution should be exercised when interpreting the results of the present study. In this regard, the present findings do not challenge the prognostic value of LVM or LVMI in contrast to LVM inappr . Indeed, although not improving EF, antihypertensive therapy nevertheless also decreased LVM in participants with appropriate LVM, and this is likely to be of prognostic importance. However, the present study does indicate that future prospective studies specifically assessing the impact of regression of increases in LVM inappr independent of absolute LVM or LVMI on the development of heart failure with a reduced EF are required.
A limitation of the present study is that it was conducted in one ethnic group with a high prevalence of increased LVM inappr and with higher thresholds for an increased LVM inappr determined in a healthy sample than that reported on in other ethnic groups. However, the thresholds for LVM inappr corresponded with thresholds of LVMI of 51.8 g/m 2.7 in the healthy sample, an accepted threshold for LVMI in this ethnic group. 32 An additional potential limitation is that we determined LVM inappr using predicted LVM values calculated from a formula derived in an alternative population. 36 However, in support of the suitability of the calculation of LVM inappr in the patients studied, in contrast to strong positive correlations noted between LVM (or LVMI) and stroke work, when LVM was expressed as LVM inappr , no residual relations with stroke work were observed. Moreover, the lack of ability to show reduced on-treatment decreases in BP and wall stress in response to antihypertensive therapy in the participants with an increased LVM inappr as compared with those participants with an appropriate LVM may reflect a type II statistical error. However, this is likely to have biased against the results of the present study and, hence, resulted in an underestimation of the size effect on EF that antihypertensive therapy could achieve in participants with an increased LVM inappr .
In conclusion, in the present study we show that, with adjustments for LV wall stress and other confounders, in mild-to-moderate hypertension, treatment-induced decreases in LVM in excess of that predicted by LV workload (LVM inappr ) were strongly related to improvements in on-treatment EF independent of absolute LVM or LVMI. These data, therefore, support the notion that LVH, as indexed by LVM or LVMI, incorporates a component of LVH that can be viewed as a compensatory change that preserves EF, but when this exceeds that predicted by LV workload, this excess in LV growth or associated changes may account for decreases in EF. Future prospective studies specifically assessing the impact of regression of increases in LVM inappr independent of absolute LVM or LVMI on the development of heart failure with a reduced EF are required.
Perspectives
Currently there is considerable uncertainty as to whether LVH contributes to decreases in systolic chamber function. Although, LVM predicts the development of a reduced EF 8 ; an increased LVM [11] [12] [13] or on-treatment decreases in LVM 14 have been associated with an unchanged EF. Furthermore, LVH may be associated with an enhanced EF for that predicted by wall stress, 15 and on-treatment decreases in LVM have been related to reductions in indices of systolic chamber function. 16 A possible explanation for these discrepancies is that LVM incorporates a component of LVH that is compensatory in nature, as well as a component that contributes to decompensation. Indeed, in cross-sectional studies, [18] [19] [20] [21] [22] [23] [24] LVM in excess of that predicted by workload (LVM inappr ) 17 is inversely associated with systolic chamber function. In the present study, we provide the first longitudinal intervention data showing that regression of LVH as indexed by LVM inappr , but not LVM or LVMI, is associated with improvements in EF independent of load, LVM, and LVMI. Hence, although LVH is a compensatory change that preserves EF, when LVH is in excess of that predicted by stroke work, it is a pathophysiological process that accounts for reduced EF. 
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